key: cord-0263084-0t9q467e
authors: Angkasekwinai, N.; Sewatanon, J.; Niyomnaitham, S.; Phumiamorn, S.; Sukapirom, K.; Sapsutthipas, S.; Sirijatuphat, R.; Wittawatmongkol, O.; Senawong, S.; Mahasirimongkol, S.; Trisiriwanich, S.; Chokephaibulkit, K.
title: Safety and Immunogenicity of CoronaVac and ChAdOx1 Against the SARS-CoV-2 Circulating Variants of Concern (Alpha, Delta, Beta) in Thai Healthcare Workers
date: 2021-10-07
journal: nan
DOI: 10.1101/2021.10.03.21264451
sha: 692f392ef65bf832cc694c1e011dd965b7c8dbed
doc_id: 263084
cord_uid: 0t9q467e

Importance: Inactivated vaccine (CoronaVac) and chimpanzee adenovirus-vector vaccine (ChAdOx1) have been more available in resource-limited settings. However, the data comparing between these two vaccines in the same setting are limited. Objectives: To determine adverse events (AEs) and immunogenicity of CoronaVac and ChAdOx1 in health care workers (HCWs). Design: This prospective study was conducted from February to July 2021. Setting: A single center, university-based tertiary care center in Bangkok. Participants: Healthy HCWs. Exposure: Two doses of CoronaVac (4 weeks apart) or ChAdOx1 (8 weeks apart) intramuscularly. Main Outcomes and Measures: Self-reported AEs were collected for 7 days following each vaccination using electronic diary. The immunogenicity was determined by the level of IgG antibodies against receptor binding domain (RBD) of the SARS-CoV-2 spike protein (S1 subunit). The 50% plaque reduction neutralization tests against original Wuhan strain and circulating VOCs were performed in subset of samples at 2 weeks after the second dose. Results: Of the 360 HCWs, 180 received each vaccine. The median (interquartile range: IQR) age was 35 (29-44) years old and 84.2% were female. Participants who received ChAdOx1 reported higher frequency of AEs than those received CoronaVac after both the first dose (84.4% vs. 66.1%, P < 0.001) and second dose (75.6% vs. 60.6%, P = 0.002), with more AEs in those younger than 30 years of age for both vaccines. The seroconversion rate was 75.6% and 100% following the first dose of CoronaVac and ChAdOx1, respectively. All participants seroconverted at 2 weeks after the second dose. The anti-SARS-CoV-2 RBD IgG levels induced by CoronaVac was lower than ChAdOX1 with geometric means of 164.4 and 278.5 BAU/mL, respectively (P = 0.0066). Both vaccines induced similar levels of neutralizing antibodies against the Wuhan strain, geometric mean titer (GMT) of 337.4 vs 331.2; however, CoronaVac induced significantly lower GMT against Alpha (23.1 vs. 92.5), Delta (21.2 vs. 69.7), and Beta (10.2 vs. 43.6) variants, respectively. Conclusions and Relevance: CoronaVac induces lower measurable antibodies but with lower frequency of AEs than ChAdOx1. The low neutralizing antibodies against the circulating VOCs induced by CoronaVac supports the need for earlier boosting to prevent breakthrough infections. Trial Registration: TCTR20210720002 https://www.thaiclinicaltrials.org/

( 4 weeks apart) or ChAdOx1 following the first dose of CoronaVac and ChAdOx1, respectively. All participants seroconverted at 2 weeks after the second dose. The anti-SARS-CoV-2 RBD IgG levels induced . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Conclusions and Relevance: CoronaVac induces lower measurable antibodies but with lower frequency of AEs than ChAdOx1. The low neutralizing antibodies against the circulating VOCs induced by CoronaVac supports the need for earlier boosting to prevent breakthrough infections.

Trial Registration: TCTR20210720002 https://www.thaiclinicaltrials.org/ . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

Vaccination has been the most effective measure to control the outbreaks of coronavirus diseases-2019 ( COVID-19). Although the immunogenicity and efficacy reported in phase III of different vaccines varied, all vaccines that passed the WHO Emergency Use Listing Procedure ( EUL) have been shown to prevent severity and mortality of COVID-19. Due to its urgency, the data available at the stage of approval for emergency use are generally limited. The adverse events in various settings as well as rare adverse events are unknown. [1] [2] [3] [4] Most resource-limited settings had limited access to vaccines in early 2021. In most part of Asia, including Thailand, the whole-cell inactivated vaccines such as CoronaVac 

AstraZeneca/Oxford) were available for procurement earlier than other vaccines. The phase III trials indicated 76% efficacy of ChAdOx1 and 50.8% efficacy of CoronaVac in preventing symptomatic infection, and both vaccines effectively prevented severe diseases with 100% efficacy. [5] [6] [7] Since the studies were conducted in different settings and with limitations, the efficacy in real world may differ from the trials due to heterogeneity of the population receiving the vaccines. The variants of interest ( VOIs) and concern ( VOCs) that are impacting on transmissibility and disease severity emerged during the late 2020, posing the risk of breakthrough infections, either after natural infections or after vaccination. 8, 9 A previous study found three to five fold lower neutralizing titers against the Alpha ( B1.1.7) and Delta ( B1.1617.2) variants compared with the original strain. 10 In many settings, the Alpha variant was predominant in April 2021, but has since been taken over by the Delta variant in August 2021.

The Beta variant has also emerged in many areas, but, like the other VOCs, it has been generally . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted October 7, 2021. ; https://doi.org/10.1101/2021.10.03.21264451 doi: medRxiv preprint out-competed by the more infectious Delta. The appearance of these VOCs raised the concern of reduced effectiveness of the COVID-19 vaccines that are widely used.

Healthcare workers ( HCWs) are the priority population for COVID-19 vaccination due to an increased risk of exposure to SARS-CoV-2. 11 To ensure the efficacy and safety of the COVID-19 vaccines, CoronaVac and ChAdOx1, which have been widely used in many settings, we investigate the adverse events and immunogenicity following the vaccination of these two vaccines in the same setting including the comparison with convalescent sera from natural infected individuals.

This single-center prospective cohort study enrolled 360 healthy HCWs aged 18 years or older at Siriraj Hospital, a university-based referral center located in Bangkok, Thailand from February to July 2021. The participants were excluded from the study if they had the following conditions: confirmed SARS-CoV-2 infection, had received current prophylactic treatment or investigational agents against COVID-19 within 90 days, had unstable underlying diseases that may compromise the immune responses, had a history of vaccine hypersensitivity, were pregnant, were immunocompromised or receiving immunosuppressive agent. The study protocol was approved by the Siriraj Institutional Review Board ( COA no. Si 171/2021).

After providing written informed consent, the participants were randomly assigned to receive either two doses of CoronaVac at 4 weeks interval or two doses of ChAdOx1 at 10 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted October 7, 2021. ; https://doi.org/10.1101/2021.10.03.21264451 doi: medRxiv preprint weeks interval. The HCWs aged 60 years or older were assigned to ChAdOx1 based on the local guidelines at that time. The participants were observed for at least 30 minutes following the vaccination for any immediate adverse events. The participants were instructed to submit selfassessment report using an electronic diary The convalescent sera of the mildly symptomatic patients recovered from D614G strain infections in late December 2020 and Delta strain in June 2021, collected by the Ministry of Public Health (MOPH) at 2 weeks of illness, were tested for PRNT50 against Delta variant as reference. Any titers below the detection limit of PRNT 50 , which is 1:10 will be indicated as an average of 1:5 for statistical analyses. Briefly, Vero cells were seeded at 2x10 5 cells/well/3 mL and placed in 37°C, 5% CO 2 incubator for 1 day. Sera were serially diluted at 1:10, 1:40, 1:160 and 1:640, respectively. The SARS-CoV-2 virus was diluted in culture medium . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 

The AEs endpoints were presented as frequencies and the Chi-square test was used to test for statistical difference. The immunological endpoints including the level of anti-SARS-CoV-2 RBD IgG and PRNT 50 titer were reported as geometric mean (Table 1) .

Subjects who received ChAdOx1 reported any AEs more frequent than CoronaVac recipients following the first and second dose vaccinations Among those who received ChAdOx1 vaccine, the anti-SARS-CoV-2 RBD IgG levels at 4 weeks after the second dose varied by age group ( P < 0.0001 by ANOVA) with a trend towards higher levels in younger age groups. This age-related response was not seen in CoronaVac group (P = 0.058, Figure 3B ). Figure S1 ). None but one subject who received . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted October 7, 2021. 

Our study provided important knowledge about AEs, immunogenicity and dynamics of the immune responses induced by CoronaVac and ChAdOx1 in the same population at the same time. We also evaluated the neutralizing antibody titers induced by the vaccines against circulating VOCs. This study is relevant to many settings where these two vaccines are widely used, especially during outbreaks caused by VOCs.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted October 7, 2021. than those reported in the phase III trial (86% in participants age 18-55 years) 12 , but closer to the rate of 59% reported in the United Kingdom (UK) where a self-reporting application was used. 13 Systemic AEs for both vaccines were significantly higher in the vaccinees younger than 30 years of age with more AEs reported by females following the second dose. This was consistent with the self-report application in the UK. For CoronaVac, the AEs rates were similar to those reported in a phase II trial in China and a phase III trial in Brazil 6, 7 , but the higher AE rate in younger individuals has not been reported.

Overall, the anti-SARS-CoV-2 RBG IgG induced by the ChAdOx1 was significantly is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted October 7, 2021. ; https://doi.org/10.1101/2021.10.03.21264451 doi: medRxiv preprint 28.6% ( 95% CI = 19.2-29.2%) of the mean convalescent level. 16 Using this assumption, based on our data, both vaccines would not provide effective protection against the Delta variant, but breakthrough VOC infections would be more likely in those who had received CoronaVac.

The presence of anti-SARS-CoV-2 NP antibody is used as the marker for natural infection and is expected to be positive following whole virus inactivated vaccine. However, we found positive anti-SARS CoV-2 NP antibody in only about half of the CoronaVac recipients, consistent with a previous report 17 . This could suggest that CoronaVac is not as immunogenic as natural infection.

After completing 2 doses of both vaccines, the level of anti-SARS CoV-2 RBD IgG in the blood peaks at 2 weeks before declining by 1.5 to 1.7 times at 4 weeks and 3 to 5 times at 8-12 weeks afterward. This half-life is shorter than that suggested for the half-life of neutralizing antibody of 108 days. 16 Our data also suggests that the peak anti-SARS-CoV-2 RBD IgG antibody response is best measured around 2 weeks after completing the 2-dose schedule.

Consistent with the previous study 18 , we found a strong positive correlation of neutralizing antibodies and anti-SARS-CoV-2 RBD IgG, supporting the use of anti-SARS-CoV-2 RBD IgG as a proxy marker for neutralizing antibodies.

This study has several limitations. Although the strength of this study is the homogeneity of the population, the population included only healthy HCWs, which may not be able to generalize to other population. In addition, only a subset of participants with small sample size were tested for the PRNT 50 against the VOCs; however, the difference was able to be demonstrated. This study also lacks the data of cell-mediated immune responses, which could be another important factor to control the severity of viral infection. This study adds to the limited data available for CoronaVac and ChAdOx1 in the Asian population and provides direct . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted October 7, 2021. ; https://doi.org/10.1101/2021.10.03.21264451 doi: medRxiv preprint comparison of these two vaccines particularly against the VOCs by using the gold-standard measurement of neutralizing antibody.

CoronaVac and ChAdOx1 are well tolerated vaccines and equally immunogenic for original Wuhan strain. However, the ChAdOx1 induced more AEs 

All authors declare no personal or professional conflicts of interest, and no financial support from the companies that produce and/or distribute the drugs, devices, or materials described in this report.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted October 7, 2021. ; https://doi.org/10.1101/2021.10.03.21264451 doi: medRxiv preprint 

COVID-19 vaccine development pipeline gears up

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

Reserving coronavirus disease 2019 vaccines for global access: cross sectional analysis

Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials

Development of an inactivated vaccine candidate for SARS-CoV-2

Double-Blind, Randomized, Placebo-Controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of treating Healthcare Professionals with the Adsorbed COVID-19 (Inactivated) Vaccine Manufactured by Sinovac -PROFISCOV: A structured summary of a study protocol for a randomised controlled trial

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebocontrolled, phase 1/2 clinical trial

Resurgence of COVID-19 in Manaus, Brazil, despite high seroprevalence

Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization

WHO SAGE values framework for the allocation and prioritization of COVID-19

Safety and immunogenicity of ChAdOx1

nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial

Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study

Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum

CoronaVac induces lower neutralising activity against variants of concern than natural infection

Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection

Dynamic of humoral response to SARS-CoV-2 anti Nucleocapsid and Spike proteins after CoronaVac vaccination

CoV-2 Variants. N Engl J Med. 2021;384(23):2212-8.. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted October 7, 2021. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted October 7, 2021. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.